Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by retiredcopon Nov 28, 2022 8:15am
225 Views
Post# 35133233

The Bleeding continues

The Bleeding continueshttps://www.science.org/content/article/second-death-linked-potential-antibody-treatment-alzheimer-s-disease

Just a day before they are suppposed to present their data at the clinical trials conference , another potential death that could be attributed to brain bleeding, this time the severe reaction with a anti-clotting medicine.  
I am sure this is going to be on everyones mind and it will be very very interesting to see the questions and comments /opinions of experts after this presentation. Big question " will it impact how the FDA  looks at the fast track approval for this porduct "  
If you examine this report , that same thing jumps out at you " this company is trying to remove the amyloid plaque from the brain" 
This could have a very positive outlook for  companies like PMN that are dealing with the misfolded oligomer and ignoring the plaque as the main culprit in AD.    
<< Previous
Bullboard Posts
Next >>